475 related articles for article (PubMed ID: 27405651)
21. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
22. Comparison of estrogen receptors, progesterone receptors and HER-2/neu expression between primary and metastatic breast carcinoma.
Azam M; Qureshi A; Mansoor S
J Pak Med Assoc; 2009 Nov; 59(11):736-40. PubMed ID: 20361669
[TBL] [Abstract][Full Text] [Related]
23. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
[TBL] [Abstract][Full Text] [Related]
24. Receptor expression discrepancy between primary and metastatic breast cancer lesions.
Karagöz Özen DS; Ozturk MA; Aydin Ö; Turna ZH; Ilvan S; Özgüroglu M
Oncol Res Treat; 2014; 37(11):622-6. PubMed ID: 25427579
[TBL] [Abstract][Full Text] [Related]
25. Receptor discordance and phenotype change in metastatic breast cancer.
Kao JY; Tsai JH; Wu TY; Wang CK; Kuo YL
Asian J Surg; 2021 Jan; 44(1):192-198. PubMed ID: 32622530
[TBL] [Abstract][Full Text] [Related]
26. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
Monaco SE; Wu Y; Teot LA; Cai G
Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
[TBL] [Abstract][Full Text] [Related]
27. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Pizzuti L; Krasniqi E; Barchiesi G; Della Giulia M; Izzo F; Sanguineti G; Marchetti P; Mazzotta M; Giusti R; Botticelli A; Gamucci T; Natoli C; Grassadonia A; Tinari N; Iezzi L; Tomao S; Tomao F; Tonini G; Santini D; Astone A; Michelotti A; De Angelis C; Mentuccia L; Vaccaro A; Magnolfi E; Gelibter A; Magri V; Cortesi E; D'Onofrio L; Cassano A; Rossi E; Cazzaniga M; Moscetti L; Omarini C; Piacentini F; Fabbri MA; Scinto AF; Corsi D; Carbognin L; Bria E; La Verde N; Samaritani R; Garufi C; Barni S; Mirabelli R; Sarmiento R; Veltri EM; D'Auria G; Paris I; Giotta F; Lorusso V; Cardillo F; Landucci E; Mauri M; Ficorella C; Roselli M; Adamo V; Ricciardi GRR; Russo A; Berardi R; Pistelli M; Fiorio E; Cannita K; Sini V; D'Ostilio N; Foglietta J; Greco F; Zamagni C; Garrone O; Di Cocco B; Baldini E; Livi L; Desideri I; Meattini I; Sarobba G; Del Medico P; De Tursi M; Generali D; De Maria R; Risi E; Ciliberto G; Sperduti I; Villa A; Barba M; Di Leo A; Vici P
Int J Cancer; 2020 Apr; 146(7):1917-1929. PubMed ID: 31330065
[TBL] [Abstract][Full Text] [Related]
28. Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution.
Chen R; Qarmali M; Siegal GP; Wei S
Mod Pathol; 2020 Dec; 33(12):2499-2506. PubMed ID: 32620918
[TBL] [Abstract][Full Text] [Related]
29. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer.
Erdem GU; Altundag K; Ozdemir NY; Sahin S; Demirci NS; Karatas F; Bozkaya Y; Aytekin A; Tasdemir V; Aslan AC; Sever AR; Zengin N
J BUON; 2017; 22(2):365-376. PubMed ID: 28534357
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
[TBL] [Abstract][Full Text] [Related]
31. Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis.
Yao ZX; Lu LJ; Wang RJ; Jin LB; Liu SC; Li HY; Ren GS; Wu KN; Wang DL; Kong LQ
Med Oncol; 2014 Jan; 31(1):798. PubMed ID: 24307349
[TBL] [Abstract][Full Text] [Related]
32. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Singhal H; Greene ME; Tarulli G; Zarnke AL; Bourgo RJ; Laine M; Chang YF; Ma S; Dembo AG; Raj GV; Hickey TE; Tilley WD; Greene GL
Sci Adv; 2016 Jun; 2(6):e1501924. PubMed ID: 27386569
[TBL] [Abstract][Full Text] [Related]
33. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.
Shabaik A; Lin G; Peterson M; Hasteh F; Tipps A; Datnow B; Weidner N
Diagn Cytopathol; 2011 May; 39(5):328-32. PubMed ID: 21488175
[TBL] [Abstract][Full Text] [Related]
34. Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases.
Yamanouchi K; Kuba S; Eguchi S
Surg Today; 2020 Jul; 50(7):657-663. PubMed ID: 31190183
[TBL] [Abstract][Full Text] [Related]
35. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
[TBL] [Abstract][Full Text] [Related]
36. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
[TBL] [Abstract][Full Text] [Related]
37. [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].
Wang B; Guan ZZ; Liu DG; Lin TY; Zhang L; Xia ZJ; Teng XY
Ai Zheng; 2004 Dec; 23(12):1710-3. PubMed ID: 15601567
[TBL] [Abstract][Full Text] [Related]
38. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.
Yang YF; Liao YY; Yang M; Peng NF; Xie SR; Xie YF
Med Oncol; 2014 Oct; 31(10):214. PubMed ID: 25216864
[TBL] [Abstract][Full Text] [Related]
39. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance.
Idirisinghe PK; Thike AA; Cheok PY; Tse GM; Lui PC; Fook-Chong S; Wong NS; Tan PH
Am J Clin Pathol; 2010 Mar; 133(3):416-29. PubMed ID: 20154280
[TBL] [Abstract][Full Text] [Related]
40. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
